CN102281875B - 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法 - Google Patents

预防、治疗或应对转移癌的使用axl抑制剂的组合疗法 Download PDF

Info

Publication number
CN102281875B
CN102281875B CN201080004818.0A CN201080004818A CN102281875B CN 102281875 B CN102281875 B CN 102281875B CN 201080004818 A CN201080004818 A CN 201080004818A CN 102281875 B CN102281875 B CN 102281875B
Authority
CN
China
Prior art keywords
optionally substituted
benzo
dihydro
pyridazin
cycloheptatrieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080004818.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102281875A (zh
Inventor
等泰道
S·霍兰
D·G·帕扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CN102281875A publication Critical patent/CN102281875A/zh
Application granted granted Critical
Publication of CN102281875B publication Critical patent/CN102281875B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201080004818.0A 2009-01-16 2010-01-15 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法 Active CN102281875B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14544809P 2009-01-16 2009-01-16
US61/145,448 2009-01-16
PCT/US2010/021275 WO2010083465A1 (en) 2009-01-16 2010-01-15 Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer

Publications (2)

Publication Number Publication Date
CN102281875A CN102281875A (zh) 2011-12-14
CN102281875B true CN102281875B (zh) 2017-09-22

Family

ID=41683427

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080004818.0A Active CN102281875B (zh) 2009-01-16 2010-01-15 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法

Country Status (13)

Country Link
US (5) US8546433B2 (https=)
EP (1) EP2387395B1 (https=)
JP (2) JP5858789B2 (https=)
CN (1) CN102281875B (https=)
AU (1) AU2010204578B2 (https=)
BR (1) BRPI1007046B1 (https=)
CA (1) CA2749843C (https=)
ES (1) ES2528032T3 (https=)
PL (1) PL2387395T3 (https=)
PT (1) PT2387395E (https=)
RU (1) RU2555326C2 (https=)
SG (1) SG172997A1 (https=)
WO (1) WO2010083465A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884119B2 (en) * 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
CA2710046C (en) * 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
US8012965B2 (en) 2006-12-29 2011-09-06 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2078010B1 (en) 2006-12-29 2014-01-29 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2205592B1 (en) * 2007-10-26 2013-05-08 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
ES2537480T3 (es) 2008-07-09 2015-06-08 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl
JP5613156B2 (ja) 2008-07-09 2014-10-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な架橋二環ヘテロアリール置換トリアゾール
JP4644273B2 (ja) * 2008-07-15 2011-03-02 本田技研工業株式会社 車両周辺監視装置
PL2387395T3 (pl) 2009-01-16 2015-03-31 Rigel Pharmaceuticals Inc Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym
WO2011035540A1 (zh) 2009-09-28 2011-03-31 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物
GB201207722D0 (en) 2012-05-02 2012-06-13 Bergenbio As Method
EP3184121A3 (en) 2012-07-25 2017-09-27 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
AU2014353006B2 (en) 2013-11-20 2019-04-04 Signalchem Life Sciences Corp. Quinazoline derivatives as TAM family kinase inhibitors
US10233176B2 (en) 2013-11-27 2019-03-19 Signalchem Lifesciences Corporation Aminopyridine derivatives as TAM family kinase inhibitors
EP3076966A2 (en) 2013-12-02 2016-10-12 BerGenBio AS Use of kinase inhibitors
WO2015156674A2 (en) * 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US10028958B2 (en) * 2014-04-19 2018-07-24 Massachusetts Institute Of Technology Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors
GB201420285D0 (en) 2014-11-14 2014-12-31 Bergenbio As Process
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
CN106083764B (zh) * 2016-07-11 2018-09-18 上海皓元生物医药科技有限公司 一种用于制备axl抑制剂的高纯度中间体的手性拆分方法
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
EP3703731A4 (en) * 2017-11-04 2021-07-21 Aravive Biologics, Inc. METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS
SG11202101955SA (en) * 2018-09-18 2021-03-30 Signalchem Lifesciences Corp Combination therapy for treating blood cancer
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
WO2022220227A1 (ja) * 2021-04-14 2022-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロピリドピリミジン化合物
GB202209285D0 (en) 2022-06-24 2022-08-10 Bergenbio Asa Dosage regimen for AXL inhibitor
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083354A1 (en) * 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
WO2008083367A2 (en) * 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1403866A (en) 1971-12-06 1975-08-28 Wyeth John & Brother Ltd Derivatives of 3-amino-1,2,4-triazoles
US4512992A (en) 1980-06-13 1985-04-23 Burroughs Wellcome Co. Treatment with dialkoxy pyridopyrimidine compounds
MX19185A (es) 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
US6258360B1 (en) 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5750545A (en) 1993-07-23 1998-05-12 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
GB9918180D0 (en) 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
MXPA03005777A (es) 2000-12-22 2005-02-14 Johnson & Johnson Derivados de triazol diaminas sustituidos como inhibidores de cinasa.
DE10123586A1 (de) 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
WO2003075917A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
EP1504047B1 (en) 2002-05-03 2007-12-12 Janssen Pharmaceutica N.V. Polymeric microemulsions
CA2501719C (en) 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
US8574827B2 (en) 2002-10-29 2013-11-05 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
EP1613625A1 (en) 2003-03-14 2006-01-11 AstraZeneca AB Novel fused triazolones and the uses thereof
US7585878B2 (en) 2003-06-12 2009-09-08 Astellas Pharma Inc. Benzamide derivative or salt thereof
WO2005013982A1 (en) 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
CA2554925A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
CA2555825A1 (en) 2004-02-11 2005-08-25 Janssen Pharmaceutica N.V. Process for the preparation of substituted triazole compounds
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
CA2575466A1 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of atp-utilizing enzymes
CN101039933B (zh) 2004-09-17 2012-06-06 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的二氨基三唑化合物
ATE485042T1 (de) 2004-10-21 2010-11-15 Vertex Pharma Triazole als hemmer von proteinkinasen
WO2006050249A1 (en) 2004-10-29 2006-05-11 Vertex Pharmaceuticals Incorporated Diaminotriazole compounds useful as inhibitors of protein kinases
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US7884119B2 (en) 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
WO2007118149A2 (en) 2006-04-07 2007-10-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
FR2908131B1 (fr) 2006-11-03 2009-01-09 Univ Haute Alsace Etablissemen Derives d'aminobenzocycloheptene,leurs procedes de preparation et leur utilisation en therapeutique
JP2008130120A (ja) 2006-11-17 2008-06-05 Sharp Corp 光ピックアップ装置
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
WO2008083353A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
US8012965B2 (en) 2006-12-29 2011-09-06 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
BRPI0813356A2 (pt) 2007-06-15 2014-12-30 Irm Llc Inibidores de proteína quinase e métodos para uso dos mesmos
EP2205592B1 (en) 2007-10-26 2013-05-08 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
ES2537480T3 (es) 2008-07-09 2015-06-08 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl
JP5613156B2 (ja) 2008-07-09 2014-10-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な架橋二環ヘテロアリール置換トリアゾール
PL2387395T3 (pl) * 2009-01-16 2015-03-31 Rigel Pharmaceuticals Inc Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083354A1 (en) * 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
WO2008083367A2 (en) * 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

Also Published As

Publication number Publication date
BRPI1007046B1 (pt) 2019-07-16
PT2387395E (pt) 2015-02-04
WO2010083465A1 (en) 2010-07-22
ES2528032T3 (es) 2015-02-03
US20170042891A1 (en) 2017-02-16
US8546433B2 (en) 2013-10-01
CA2749843C (en) 2017-09-05
US20130338161A1 (en) 2013-12-19
AU2010204578B2 (en) 2016-05-12
US20210379064A1 (en) 2021-12-09
EP2387395B1 (en) 2014-10-15
SG172997A1 (en) 2011-08-29
PL2387395T3 (pl) 2015-03-31
US20100196511A1 (en) 2010-08-05
RU2555326C2 (ru) 2015-07-10
JP2012515225A (ja) 2012-07-05
CN102281875A (zh) 2011-12-14
BRPI1007046A2 (pt) 2015-07-21
AU2010204578A1 (en) 2011-07-28
US20190336500A1 (en) 2019-11-07
EP2387395A1 (en) 2011-11-23
JP2015007135A (ja) 2015-01-15
CA2749843A1 (en) 2011-07-22
RU2011132118A (ru) 2013-02-27
JP5858789B2 (ja) 2016-02-10
HK1164146A1 (en) 2012-09-21

Similar Documents

Publication Publication Date Title
CN102281875B (zh) 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法
JP7549627B2 (ja) Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法
CA2779105C (en) Kinase inhibitors
CN109071542B (zh) 可用作rsk抑制剂的羧酰胺衍生物
EP2326641B1 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
KR101700454B1 (ko) 피리미딘-2-아민 화합물 및 ｊａｋ 키나제 억제제로서의 그의 용도
EP2114954B1 (en) Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2484679B1 (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
US20210238196A1 (en) Spiro aromatic ring compound and application thereof
CN115368383A (zh) 稠合含氮杂环类化合物、其制备方法及其在医药上的应用
HK1164146B (en) Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2024227026A1 (en) Heterocyclic compounds as parp1 inhibitors
HK1260540A1 (en) Carboxamide derivatives useful as rsk inhibitors
HK1260540B (zh) 可用作rsk抑制剂的羧酰胺衍生物
HK1174631B (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant